Former FDA Deputy Director and Talecris executive adds extensive
clinical, regulatory and manufacturing experience to Company's Board
TSX: HAE
MONTREAL, Oct. 1 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX: HAE) announced today the appointment of Thomas J. Lynch, J.D., Ph.D. to the Company's Board of Directors. Dr. Lynch, former Deputy Director, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), currently serves as Senior Vice President Compliance, Regulatory Affairs and Public Policy for Talecris Biotherapeutics.
"Dr. Lynch brings extensive clinical, regulatory and manufacturing experience in the area of blood products and a broad strategic perspective to our Board of Directors. We are pleased to welcome him as an independent director," said Joseph Galli, Haemacure's Chairman and Chief Executive Officer. "Thomas' distinguished background and relevant expertise will be a valuable addition to our Board as we continue to make progress toward initiating a pivotal Phase II/III clinical trial for our lead product candidate, Hemaseel(R)HMN (fibrin sealant), for biosurgical hemostasis" concluded Mr. Galli.
From 2003-2005, Dr. Lynch served as Vice President, Regulatory Affairs
and Quality Assurance at CryoLife, Inc., a manufacturer of medical tissues,
heart valves and oncology drugs, where he was responsible for, among other
things, ensuring compliance with domestic and international laws,
regulations, governing the design, manufacture, and distribution of medical
devices, biological products and human tissues. Prior to joining CryoLife,
Dr. Lynch served as Senior Vice President, Regulatory Affairs and Quality
Assurance at Clearant Inc., a biotechnology company developing pathogen
inactivation technology for the biological products market. Dr. Lynch also
served as Deputy Director, Division of Hematology, Office of
'/>"/>
| SOURCE HAEMACURE CORPORATION Copyright©2008 PR Newswire. All rights reserved |